Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share Dump

<< Previous

Bullboard Posts

Next >>

Post by Forestviewon Jan 28, 2021 10:15am

213 Views

Post# 32408585

Share Dump

I'm wondering if this share dump is people selling in order to buy GME, AMC, NOK, BB, etc. The mentality being they can make a quick buck and come back to ATE. Again, it's dropping on no news. It's one thing if they released news that was negative. This is just extraneous impacts.

<< Previous

Bullboard Posts

Next >>

Does Canada have any companies in the computer chip industry?